14 patents
Utility
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
2 Jan 24
The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject.
Dylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Nathan Schmidt, Mark Simon
Filed: 11 Aug 22
Utility
Bacteria engineered to treat diseases associated with hyperammonemia
19 Dec 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 16 Dec 20
Utility
Microorganisms engineered to reduce hyperphenylalaninemia
26 Sep 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
Filed: 3 Jun 22
Utility
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
15 Aug 23
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li
Filed: 11 Jan 17
Utility
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
27 Jun 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Sep 16
Utility
Bacteria engineered to reduce hyperphenylalaninemia
4 Apr 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
Filed: 16 Nov 16
Utility
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
18 Oct 22
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
Filed: 5 Jan 18
Utility
Bacteria engineered to treat liver disease
13 Sep 22
The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts.
Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
Filed: 31 May 19
Utility
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
12 Jul 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Sep 16
Utility
Bacteria engineered to treat metabolic diseases
5 Apr 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet, Adam Fisher
Filed: 24 Jun 16
Utility
Bacteria engineered to treat disorders in which oxalate is detrimental
15 Mar 22
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
Filed: 31 Aug 16
Utility
Bacteria engineered to treat diseases associated with hyperammonemia
13 Jul 21
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 18 May 17
Utility
Bacteria engineered to treat a disease or disorder
2 Mar 21
Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
Filed: 22 Dec 17
Utility
Bacteria engineered to reduce hyperphenylalaninemia
6 Apr 20
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
Filed: 12 May 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first